

Tocilizumab (ACTEMRA) Infusion Therapy Plan Orders

Printed Name: _____

Page 1 of 2

Name:
Kaiser Permanente Member I.D. #
Date of Birth

Instructions to Provider

Review orders and note any changes. All orders with \(\text{\overline{A}} \) will be placed unless otherwise noted. Please fax completed order

	e receiving treatment (see fax numbers at the end of this protocol). rders via usual method. Lab monitoring is the responsibility of the ordering				
Please complete all of the following:					
☐ Pre-Service Authorization has been obtain	ed by Kaiser Permanente Fax: 1-888-282-2685 Voice : 1-800-289-1363				
	Diagnosis:				
Order Date:	ICD-10 code (REQUIRED):				
Weight:kg	ICD-10 description				
General Plan Communication					
Special instructions/notes:					
Provider Information					
	nti-rheumatic therapy may cause reactivation of hepatitis B				
 Ensure baseline PPD or quantiFERON- 					
	urrently or within 3 months of discontinuation of therapy				
 Do not combine with tumor necrosis factors 	tor (TNF) agents or other biologic DMARDs.				
 Patient requires monitoring of CBC w/di 	ff and AST/ALT every 4 weeks prior to each treatment.				
Review lipid panel 4 and 8 weeks after	initiation, then every 6 months.				
Infusion Therapy					
✓ tocilizumab (ACTEMRA) in 0.9%	sodium chloride 100 mL IV infusion				
Dose: ✓ 4 mg/kg x weight (kg) =	Total Dose mg				
\square 8 mg/kg x weight (kg) =	Total Dose mg				
Route: Intravenous					
Frequency: Once every 4 weeks					
Infuse over: 60 minutes					
If infusion-related reaction:					
	Increase primary infusion to wide open rate; 3) Administer PRN				
medications per hypersensitivity	· · · · · · · · · · · · · · · · · · ·				
Note any changes to above regime Pre-Meds	en:				
☐ acetaminophen (TYLENOL) tablet Dose: 650 mg Route: Oral Fred	uuency: Once, 30 minutes prior to tocilizumab infusion.				
	luring infusion for achiness, headache, or fever if not given prior to				
infusion.	turning initiation for dominess, meddadine, or level in flot given prior to				
cetirizine (ZYRTEC) tablet					
	nuency: Once, 30 minutes prior to tocilizumab infusion.				
	s prior to tocilizumab infusion (if not taken at home).				
	LU-CORTEF) injectable [not routine; only if breakthrough reaction]				
	<i>quency:</i> Once, 30 minutes prior to tocilizumab infusion in addition to				
	acetaminophen and antihistamine if patient still experiences symptoms with acetaminophen and				
antihistamine alone.					
Other:					
	quency: Once, 30 minutes prior to tocilizumab infusion				
✓ No routine pre-medications necessary pre-medications for future doses.	. Above medications may be given if patient has reaction and requires				
Provider Signature:	Date:				

Phone: Fax:



Tocilizumab (ACTEMRA) **Infusion Therapy Plan Orders**

Page 2 of 2

Name:
Kaiser Permanente Member I.D. #
Date of Birth

Ī	IV	Τ.	in	Δ	Ca	r۵

✓ 0.9% sodium chloride infusion 250 mL

Rate: 30 mL/hr Route: Intravenous

Start peripheral IV if no central line

heparin flush 100 unit/mL

Frequency: PRN for IV line care per Nursing Policy Dose: 500 units Route: Intracatheter

Infusion Reaction Meds

☑ albuterol (PROVENTIL) nebulizer solution 0.083%

Dose: 2.5 mg Route: Nebulization Frequency: PRN for shortness of breath/wheezing

 $\overline{\mathbf{Q}}$ diphenhydrAMINE (BENADRYL) injectable

> Dose: 25 ma Route: Intravenous Frequency: Once PRN, May repeat x1 for urticaria, pruritus, shortness of breath. May repeat in 15 minutes if symptoms not resolved.

☑ EPINEPHrine (EpiPen) 0.3 mg/0.3 mL IM Auto-Injector

Route: Intramuscular Frequency: Once PRN for anaphylaxis. Inject into lateral thigh and Dose: 0.3 mg hold for 10 seconds. Massage the injected area. Use for patients weighing greater than 27.3 kg (60 lbs). Use amp and 1.5 inch needle for patients with BMI greater than 30. Notify physician if administered.

Frequency: Run continuously to keep vein open

✓ hydrocortisone sodium succinate (SOLU-CORTEF) injectable

Route: Intravenous Frequency: Once PRN for hypersensitivity Dose: 100 mg

Lab Review for Nursing

Continue with infusion only if patient meets the following criteria:

- ANC greater than or equal to 2,000 (first dose) or greater than or equal to 1,000 (subsequent doses)
- Platelets greater than or equal to 100,000
- AST/ALT less than 1.5 x ULN
- Verify lipid panel drawn at 4 and 8 weeks after initial treatment.
- If lipid panel labs not drawn prior to treatment, instruct patient to have labs drawn and notify provider, but proceed with infusion.

Nursing Orders

- Initial dose only: Verify PPD or quantiFERON-TB assay for latent TB results are negative for TB. Do not infuse tocilizumab without negative TB results.
- Do not administer tocilizumab and notify provider if patient has a temperature greater than 100 degrees F, complains of symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection.
- Discontinue IV line when therapy complete and patient stabilized.

References

ACTEMRA® (tocilizumab) Injection, for intravenous infusion prescribing information.

Kaiser Permanente Infusion Locations

Bellevue Medical Center

11511 NE 10th St, Bellevue, WA 98004

Fax: 425-502-3512 Phone: 425-502-3510

Capitol Hill Medical Center

201 16th Ave E, Seattle WA 98112

Fax: 206-326-2104 Phone: 206-326-3109

Everett Medical Center

2930 Maple St, Everett, WA 98201

Fax: 425-261-1578 Phone: 425-261-1566

Olympia Medical Center

700 Lilly Road N.E., Olympia, WA 98506 Fax: 360-923-7106 Phone: 360-923-7164 Riverfront Medical Center - Spokane

W 322 North River Drive, Spokane, WA 99201

Phone: 509-241-2073 Fax: 509-324-7168

Silverdale Medical Center

10452 Silverdale Way NW, Silverdale, WA 98383 Fax: 360-307-7421 Phone: 360-307-7316

Tacoma Medical Center

нім

209 Martin Luther King Jr Way, Tacoma, WA 98405 Fax: 253-383-6262 Phone: 253-596-3666

Provider Signature:		Date:	
Printed Name:	Phone:	Fax:	